Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NU102
- Development stage
- Unknown
- Lead developer
- Nuclidium
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
NU102 (also known as 61Cu-TraceNET or 61Cu-NODAGA-LM3) is a copper-61-labeled radiopharmaceutical diagnostic agent developed by Nuclidium. It is a somatostatin receptor subtype 2 (SSTR2) antagonist designed for positron emission tomography (PET) imaging of SSTR2-positive tumors, including gastroenteropancreatic and bronchopulmonary neuroendocrine tumors (GEP & BP-NETs) and metastatic breast cancer. NU102 utilizes Nuclidium's proprietary CuTrace platform, which allows for rapid, room-temperature radiolabeling of the targeting peptide with high radiopurity. In clinical trials, NU102 has demonstrated high tumor uptake, a favorable tumor-to-background ratio, and the ability to detect small lesions missed by standard gallium-68 PET scans.
- Brand names
- TraceNET
- Other names
- 61Cu-TraceNetCopper-61-NODAGA-LM3Copper61-NODAGA-LM3Copper 61-NODAGA-LM3[61Cu]Cu-NODAGA-LM3
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on NU102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NU102.